More Problems For Biogen's Tysabri
This article was originally published in The Pink Sheet Daily
The most recent disappointment for the big biotech, which has been plagued by a host of issues, comes from a late-stage failure in its multiple sclerosis program, prompting pipeline discontinuations.
You may also be interested in...
Roche plans to file the selective CD20 antibody in 2016 after releasing positive Phase III data at ECTRIMS in both relapsing-remitting and primary progressive multiple sclerosis, a debilitating form of the disease for which there are no approved drugs.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.